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Abstract The introduction of biological science into the
practice of medicine was a big transforming event for the
profession, leading to different new medical models such as
predictive, preventive and personalized medicine. Each of
them is a rapidly emerging field that helps us to determine
the risk for individuals to develop specific diseases, detect
the disease’s earliest onset and prevent or intervene early
enough to provide maximum benefit for each patient.
However, to realize this new potential, new healthcare
models must be created, improved and validated. New
healthcare models that are more proactive than reactive
because prevention is less expensive than reactive medi-
cine. Current knowledge about predictive, preventive and
personalized medicine is already sufficient to implement
this approach, but there are no effective practice models,
delivery systems and appropriate reimbursement mech-
anisms. In the course of this review, we describe the
economic components and benefits of a predictive, preven-
tive and personalized health plan for lung as well as head
and neck cancer and show how prospective care could
relate to a community or group of covered individuals.
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Introduction
Head and neck carcinoma (HNC) is the sixth most common
malignancy and a major cause of cancer morbidity and
mortality worldwide. Globally about 500,000 new oral and
pharyngeal cancers are diagnosed annually and three
quarters of these are from the developing world [1]. Age
standardized incidence rate of HNC in males exceeds 30 in
100,000 populations in regions of France, Hong Kong, the
Indian subcontinent, Central/Eastern/Southern Europe,
regions of South America and among USA blacks. High
rates (higher than 10 in 100,000 populations) in females are
found in India and Hong Kong. Due to sedentary lifestyle
(e.g. heavily smoking), unhealthy nutrition (abnormal
consumption of spices, strong alcohols, etc.) and a
prolonged lifespan, the prevalence of the disease in the
developed and developing countries is further increasing
[2]. One main reason for the high prevalence is that HNC is
normally a late-diagnosed disease and is usually only
discovered when the first complications occur. Therapy of
advanced HNC in the late state is far away from therapeutic
success. Five-year survival rates for mouth, tongue,
oropharynx and laryngopharyngeal cancers seldom exceed
40%. Quick diagnostic measures and/or early prevention
are therefore critical for the control of the disease status.
The market size and huge demand for these tests make it a
model disease to develop new approaches to in-vitro
diagnostic (IVD). In this review, we briefly summarize the
overview of IVD for lung cancer and HNC, the current
commercial devices available for, and the recent work in
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the area of artificial receptors and the potential for the
development of new devices for cancer diagnosis.
Current status of lung as well as head and neck cancer
Every year more than one million new cases of HNC are
diagnosed worldwide and approximately half of those
people die. However, 1/3 of them could be saved if the
disease had been diagnosed at an earlier stage. Current used
radiological or clinical methods like MRI, CT, or even PET-
CT or clinical methods like bronchoscopy are expensive,
might be discomforting and are more often than not
inaccurate to diagnose HNC and lung cancer at an early
stage. The costs of treatment for a lung cancer and HNC
patient are between € 17,000 and € 22,000 [3–7]. Through
early detection, those costs can be significantly reduced.
Thus, there is an acute need for an early, accurate, painless
and cost-saving diagnostic method.
Customer need
The traditional process of diagnosing a disease is a
complicated one and involves up to four different parties,
depending on the condition [1] (Fig. 1).
A patient will consult his physician with certain
symptoms (e.g. pain, bleeding, coughing or dysphagia)
already present. Based on these symptoms a physician will
make a hypothesis what the disease may be. However, to
prove his theory he often requires specialized laboratory
tests. So, after a clinical exam samples will be taken and
examined by any diagnostic laboratory. When the test
results are available a treatment will be assigned by the
physician. This treatment may prove to be accurate and
leads to a stabilization/healing process or may be inaccurate
and will require further investigation. On the monetary side,
as far as the patient is insured, the costs for diagnosis are
born by the health insurer; i.e. patients have to pay
indirectly for diagnostic tests through their health insurance
contributions. However, the health insurer is only willing to
pay if laboratories are using state-of-the-art diagnostic
methods (personal communication: Prof. D. Thurnher,
Medical University of Vienna, April 2010). There are
several problems arising from this traditional method of
diagnosing for the parties involved, which will be considered
as paying and receiving customers.
Paying customers
Diagnostic laboratories
Current diagnostic methods are time consuming. They
normally require hours until the result can be validated.
Furthermore, high costs can be associated with diagnostic
instruments like CT (especially purchasing costs) (personal
communication: Prof. D. Thurnher, Medical University of
Vienna, April 2010). Therefore, it is clear that a faster and
cost-efficient instrument is needed. This would cut processing
times and associated costs.
Current diagnostics instruments are not always able to
deliver an accurate diagnosis to the doctor (e.g. cancer must
be large enough in order to be seen with CT) (personal
communication: Prof. D. Thurnher, Medical University of
Vienna, April 2010) and may lead to a wrong treatment. So,
an accurate diagnostic instrument is also needed in those
institutions.
Public and private health insurers
The late application of current diagnostic methods after
symptoms already have occurred can imply higher treat-
ment costs (longer hospital stays, etc.) especially if diseases
are diagnosed in a late stage [3]. It has been estimated for
western European countries that one lung cancer patient costs
approximately € 17,000 and one HNC patient approximately
€ 22,000 [4–7]. As a result, earlier and accurate treatment would
significantly shorten those costs (personal communication
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Fig. 1 Traditional process of
diagnosis
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April 2010). Many public health insurers are currently
experiencing financial deficits and cannot sustain their
operations in the long run without cash injections. Thus, such
an early diagnostic instrument may solve this problem
(personal communication; Prof. D. Thurnher, Medical Uni-
versity of Vienna, April 2010).
Receiving customers
Current diagnostic methods are used when symptoms are
already present. Therefore, diseases are often diagnosed in a
late stage, which means a lower survival chance for patients
[8]. The sooner a (potential) disease is diagnosed—even
before the symptoms occur—the faster and more accurate
the treatment can be. This in turn contributes to a prolonged
life expectancy of the patient [9].
Traditional forms of diagnostic instruments may be
inaccurate. An inaccurate treatment assigned because of a
wrong diagnosis can be very harmful to the patient. Therefore,
using early diagnostic instruments, an inaccurate treatment
can be prevented before it causes serious damage [10].
The need for a more accurate, cost-saving and fast
diagnostic method is acute. Especially when we look at our
market, cancer mainly caused by smoking, the following
customer pain and need can further be identified.
Cancer caused by smoking is usually found in the upper
aero-digestive tract (head and neck) or in the lungs. It is
usually diagnosed through X-Ray, CT and endoscopy (e.g.
bronchoscopy), as soon as symptoms have occurred (e.g.
coughing up phlegm with traces of blood (personal
communication: Prof. D. Thurnher, Medical University of
Vienna, April 2010)). The problems with the traditional
diagnostic methods are:
& Inaccuracy, as cancer in early stages is not visible with
CT and X-Ray;
& Discomfort and potential morbidity for patients when
using invasive diagnostic procedures;
& Costs incurred when using an expensive diagnostic
instrument like the CT.
Market overview
In vitro diagnostics market (IVD)
IVD market plays a major role in healthcare and disease
management. It affects around 70% of healthcare decisions.
The global IVD market is estimated to generate sales of
nearly $ 43.2bn in 2010 and $ 54bn by 2013. The global
market is expected to grow with a CAGR (Compound
Annual Growth Rate) of 7.1% and the European with 7%.
Consequently, the European IVD market is expected to
reach ca. $ 16bn in 2010 and $ 19.6bn in 2013. On the
whole, the European IVD market represents approximately
37% of the global IVD market in 2010 [11] (Fig. 2).
The global cancer IVD market has reached $ 7,4bn in
2009 [12] and is expected to reach $ 7.9bn in 2010. Under
the assumption that 37% of the global cancer IVD market
represents the European cancer IVD market and a CAGR of
7%, the latter is expected to reach $ 2.9bn in 2010, $ 3.8bn
in 2014 and $ 4.7bn in 2017.
Cancer market
In 2008 the global cancer market was valued at $ 47.7bn
and is expected to reach $ 76.7bn in 2014. This represents a
CAGR of 8.2% between 2008 and 2014 [13]. Cancer as a
leading cause of death is projected to continue rising with
an estimated 12 m deaths in 2030 [14]. The World Health
Organization (WHO) notes that one third of all cancer
diseases could be prevented by avoiding all cancer-related
risk factors. Another third could be cured, if only diagnosed
early and treated efficiently [15]. However, only 30–50% of
all cancer patients suffer from pain at the time of diagnosis
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Fig. 2 Global IVD market
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[16]. Therefore, the goal of the predictive medicine is the
early pre-symptomatic detection of diseases.
Concerning the European cancer market, 3.2 million
Europeans are diagnosed with cancer each year. It is the
second most common cause of death in Europe [17].
Lung cancer and HNC
There are about one million incidences of lung cancer each
year worldwide. 90% of them lead to death and 85% of
those are caused by smoking [9]. The annual incidence rate
for lung cancer in Europe accounts for 60 per 100,000
inhabitants (approximately 310,000 new cases) [18].
In Europe approximately 100,800 new HNC cases are
diagnosed annually. Around 40,000 of them die, which
makes up 40% [13]. However, the incidence rate of HNC
has doubled within the past 20 years due to the rising
tobacco and alcohol consumption and is therefore further
expected to rise [3]. About 85% of this cancer can be
related to tobacco. Furthermore, excessive alcohol con-
sumption is another risk factor for developing HNC [3].
However, significant advances and improvements can be
observed in tackling cancer within Europe. Nevertheless,
cancer remains a serious public health concern, which is
also putting a heavy financial burden on the society.
Financial burden of lung cancer and HNC
In 2001 it has been estimated that the treatment of a patient
with lung cancer costs € 17,000. These costs are split into
hospitalization which accounts for almost 50% and 13% of
chemotherapy [3]. Furthermore, the Institute for Medical
Technology Assessment at the University in Rotterdam
calculated the costs of HNC. Diagnosis, treatment and
2 years of follow-up of patients with a primary tumor were
calculated with € 21,858. For patients with a recurrent
tumor, the costs were € 27,629. The 10 years follow-up
costs were € 423. In total, the average costs of a new patient
were € 31,829 [6]. Through early detection of this diseases
and early treatment such costs can be reduced significantly.
Conclusion
In addition to their original healing-mission, physicians
gain more and more responsibility in health politics
including most important aspects like education and
medical ethics. Recent developments and possibilities such
as in prenatal diagnostics, molecular biology and in vitro-
fertilization demand clear cut positions from the medical
staff. Political evaluation of costs in healthcare systems
concerns analysis of the most common factors responsible
for the increasing costs. High expectations and demands of
the patients are one reason, other are excessive use of new
technologies, increase of the aged in the population and
growing cost for liability cases. Mechanisms for the down-
regulation of costs are restricted. The so-called free market
in healthcare such as premium-competition of health
insurance point out more theoretical than practical aspects.
The Health insurance law (KVG) by increasing the extent
of services has contributed to a further increase of costs
instead of lowering them. Shifting from hospitalization to
out-patient treatment and reducing beds for acute services
could lower hospital costs further. AIDS, Drug-politics and
environmental destruction, three actual plagues, represent
further political challenges for physicians. For the future a
reasonable politic involving a better motivated medical
corps has to be promoted. To this end first personal
structures should be strengthened by help of new ethical
view points. Future medicine should be more proactive
rather than reactive. Therefore medical responsibility in
political development is mandatory.
Outlook
There is a long continuum of differing positions amongst
academia, the private sector and the public sector in
determining the appropriate balance between providing
incentives to both innovator drug companies and generic
drug manufacturers, while at the same time also protecting
legitimate patent rights. Juxtaposed to these issues is the
fact that the cost of biomedical research is enormous and it
continues to grow as the government seeks to provide for
the health and welfare of a public that not only seeks
therapeutic medicine and medical care when sick, but also
wants prophylactic and diagnostic products. Furthermore,
personalized medicine, resulting from the advances in
functional genomics and new and increased use of lifestyle
drugs providing therapies is indicative of the ever-increasing
expectations for a greater range of products. The debate then
is not only how to make such products available but also how
to make them affordable. With more than 500 drug patents
scheduled to expire between 2004 and 2009 (with 26 of these
drugs accounting for more than 38 billion dollars in sales
annually), the stakes are high, for not only the generic and
brand name manufacturers, but also for the consumer.
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